Carotuximab

Names

[ Name ]:
Carotuximab

Biological Activity

[Description]:

Carotuximab (TRC105) is a IgG1 monoclonal antibody that blocks endoglin (CD105) and its downstream Smad signaling pathway. Carotuximab has immunomodulatory and antineoplastic actions[1][2].

[Related Catalog]:

Research Areas >> Cancer

Signaling Pathways >> Stem Cell/Wnt >> TGF-beta/Smad

Signaling Pathways >> TGF-beta/Smad >> TGF-beta/Smad

[In Vitro]

Carotuximab (TRC105；300 μg/mL；预处理 1 小时，然后共培养 12 小时) 降低人主动脉内皮细胞中 7-酮胆固醇诱导的内皮糖蛋白 (Eng) 蛋白水平和 pSmad1/5 和 pSmad2/3 信号通路。Carotuximab 介导的 Eng 阻断阻止了 7-酮胆固醇诱导的单核细胞通过内皮单层细胞的粘附和迁移[1]。 Western Blot Analysis[1] Cell Line: Human aortic endothelial cells (HAoECs) Concentration: 300 μg/mL Incubation Time: Pretreatment 1 h, and then co-cultured for 12 h Result: Reduced the 7-Ketocholesterol-induced Eng protein levels and pSmad1/5 and pSmad2/3 signaling.

[In Vivo]

Carotuximab（TRC105；2 mg/kg；i.v；每 3 天一次；持续 8 周）与 Decitabine 一起在急性髓性白血病 (AML) 异种移植物中产生更持久的抗白血病作用，并且还能增强活性氧 (ROS) 活性[2]。 Animal Model: Female NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ; 7-8 weeks) injected with primary AML-0032 cells[2] Dosage: 2 mg/kg Administration: i.v; every 3 days; for 8 weeks Result: Along with Decitabine resulted in a more durable anti-leukemic effect in AML xenografts.

[References]

[1]. Katarina Tripska , et al. Monoclonal anti-endoglin antibody TRC105 (carotuximab) prevents hypercholesterolemia and hyperglycemia-induced endothelial dysfunction in human aortic endothelial cells. Front Med (Lausanne). 2022 Sep 7;9:845918.

[2]. June Baik, et al. Therapeutic effect of TRC105 and decitabine combination in AML xenografts. Heliyon. 2020 Oct 13;6(10):e05242.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.